Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial
- 28 February 2009
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 157 (2) , 369-374
- https://doi.org/10.1016/j.ahj.2008.09.011
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Long-Term Outcomes with Drug-Eluting Stents versus Bare-Metal Stents in SwedenNew England Journal of Medicine, 2007
- Safety and Efficacy of Sirolimus- and Paclitaxel-Eluting Coronary StentsNew England Journal of Medicine, 2007
- Long-Term Versus Short-Term Clopidogrel Therapy in Patients Undergoing Coronary Stenting (from the Randomized Argentine Clopidogrel Stent [RACS] Trial)The American Journal of Cardiology, 2007
- Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysisEuropean Heart Journal, 2006
- Incidence, Predictors, and Outcome of Thrombosis After Successful Implantation of Drug-Eluting StentsJAMA, 2005
- Stent Thrombosis After Successful Sirolimus-Eluting Stent ImplantationCirculation, 2004
- Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary InterventionJAMA, 2002
- Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE studyThe Lancet, 2001
- A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery StentingNew England Journal of Medicine, 1998
- A Randomized Comparison of Antiplatelet and Anticoagulant Therapy after the Placement of Coronary-Artery StentsNew England Journal of Medicine, 1996